Summary:At-Bay: Difference between revisions

{{#if:{{{bullet|}}}|* }}🏛️ '''Governance and capital history.''' Governance has matured from startup mode to near-public-company standards with independent directors Gregg Davis and Rob Glanville added to the carrier's board in 2023, while the broader board includes founder-executives and investor representatives from Icon Ventures and Lightspeed. Capital actions span eight equity rounds from a 2016–2017 seed through the landmark $185 million Series D in July 2021 at a $1.35 billion valuation, a $20 million extension from ION Crossover Partners, and a minor $3.7 million round in September 2022 — with no further raises as of 2026. Munich Re Ventures uniquely provides both equity capital and underwriting capacity via HSB, aligning investment and risk-bearing interests.{{#if:{{{bullet|}}}||<br>}}{{#if:{{{bullet|}}}||<br>}}{{#if:{{{bullet|}}}|* }}🚀 '''Strategic outlook.''' At-Bay's forward strategy centers on deepening SME penetration through its admitted product and API distribution, expanding into adjacent specialty lines such as D&O or cyber fraud-related crime insurance, and optimizing full-stack carrier operations by gradually migrating more business onto its own balance sheet. Technology priorities include AI-enhanced threat intelligence and underwriting, expansion of the At-Bay Stance platform, and scaling MDR through automation, while the company intends to diversify reinsurance partnerships and pursue embedded insurance deals with cloud providers or MSPs. The hire of CFO Ari Fischel — who helped prepare Oscar Health for IPO — and the presence of crossover fund ION signal public-market readiness, with a roadmap to EBITDA breakeven implied by improving operating leverage and favorable unit economics.